BUZZ-Vertex Pharmaceuticals shares rise after raising 2026 revenue forecast

November 2 - ** Vertex Pharmaceuticals (VRTX.O) shares rose 2.1% in after-hours trading to $565

** The company raised its annual revenue forecast to $13.15 billion–$13.25 billion from previous guidance of $13.1 billion–$13.2 billion

** According to data compiled by London Stock Exchange Group (LSEG), the company reported third-quarter revenue of $3.44 billion, exceeding analysts' expectations of $3.42 billion

** The report shows that third-quarter adjusted earnings per share were $4.76, compared with the analysts' average estimate of $4.79

** Bank of Montreal (BMO) said this strong quarter has cleared the way for the U.S. Food and Drug Administration (FDA) to make a decision on Vertex's povetacicept for treating IgA nephropathy (link) on November 30

** As of last trading day's close, the stock has gained 22% year to date

(To facilitate non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it only to assist readers. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)